Back to Search
Start Over
Response to anti-angiogenesis: an ever changing feature.
- Source :
-
Breast (Edinburgh, Scotland) [Breast] 2011 Oct; Vol. 20 Suppl 3, pp. S61-2. - Publication Year :
- 2011
-
Abstract
- Aims: Anti-angiogenic drugs have gained international approval for the therapy of advanced breast, lung, colo-rectal, kidney and central nervous system cancer. However, the clinical benefit associated with the use of these drugs has been so far limited.<br />Methods: This review discuss the possible rational developments of a new generation anti-angiogenic drugs.<br />Conclusion: Since most of the biological and clinical activity of the currently available generation of anti-angiogenic drugs targets VEGF and its related pathways, it seems relevant to (1) better understand mechanisms of resistance and/or escape from anti-VEGF and (2) identify and validate vascular targets complementary to anti-VEGF.<br /> (Copyright © 2011 Elsevier Ltd. All rights reserved.)
- Subjects :
- Angiogenesis Inhibitors therapeutic use
Disease-Free Survival
Drug Resistance, Neoplasm
Drugs, Investigational therapeutic use
Female
Forecasting
Humans
Male
Neoplasms pathology
Prognosis
Randomized Controlled Trials as Topic
Risk Assessment
Survival Analysis
Vascular Endothelial Growth Factor A metabolism
Angiogenesis Inhibitors pharmacology
Drugs, Investigational pharmacology
Neoplasms drug therapy
Neoplasms mortality
Neovascularization, Pathologic prevention & control
Vascular Endothelial Growth Factor A antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1532-3080
- Volume :
- 20 Suppl 3
- Database :
- MEDLINE
- Journal :
- Breast (Edinburgh, Scotland)
- Publication Type :
- Academic Journal
- Accession number :
- 22015295
- Full Text :
- https://doi.org/10.1016/S0960-9776(11)70296-X